P18.37.B REPEATED CONVECTION-ENHANCED DELIVERY (CED) INFUSION OF A POLIO/RHINOVIRUS RECOMBINANT (LERAPOLTUREV; LERA) IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS, FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS OF LERA (LERA-CPLI)
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae144.353
Abstract: Phase 1 and 2 clinical trials of a single intratumoral injection of LERA (previously PVSRIPO) via CED into enhancing disease of rGBM has been shown safe and prolonged survival was observed in a subgroup of… read more here.
Keywords: lera; injections lera; ced infusion; rgbm ... See more keywords
Abstract 458: Nanoparticle-mediated delivery of miR-590-3p decreases recurrent GBM tumor growth by inhibits multiple oncogenic nodes
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-458
Abstract: Glioblastoma (GBM) is the most lethal and aggressive form of brain cancer. Despite aggressive therapy consisting of surgery followed by radio/chemotherapy GBM recurs in almost all patients and, currently, there are no proven therapies to… read more here.
Keywords: recurrent gbm; delivery; mir 590; tumor ... See more keywords
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.2003
Abstract: 2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is amplified (amp) in ~50% of GBMs and is a compelling therapeutic target. ABT-414 is… read more here.
Keywords: efficacy analysis; analysis; analysis abt; abt 414 ... See more keywords
Bevacizumab combined with re-irradiation in recurrent glioblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.961014
Abstract: Background Glioblastoma is characterized by rich vasculature and abnormal vascular structure and function. Currently, there is no standard treatment for recurrent glioblastoma (rGBM). Bevacizumab (BEV) has established role of inhibiting neovascularization, alleviating hypoxia in the… read more here.
Keywords: glioblastoma; rgbm; bev; treatment ... See more keywords